{"id":3806,"date":"2020-01-30T12:07:14","date_gmt":"2020-01-30T12:07:14","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\/"},"modified":"2020-01-30T12:07:14","modified_gmt":"2020-01-30T12:07:14","slug":"nanexa-utokar-samarbetet-med-svenskt-biotechbolag","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\/","title":{"rendered":"Nanexa ut\u00f6kar samarbetet med svenskt biotechbolag"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong><\/strong><\/div>\n<p><span><span>I slutet av 2018 tecknade\u00a0Nanexa ett &#34;Material Transfer Agreement&#34; med ett svensktbiotechbolag f\u00f6r utv\u00e4rdering av PharmaShell\u00ae\u00a0teknologin med deras specifika l\u00e4kemedelssubstans. Utv\u00e4rderingen har hittills gett bra resultat och bolaget har nu beslutat att ta projektet vidare med aktiviteter f\u00f6r att optimera formuleringen. I detta f\u00f6rl\u00e4ngda samarbete kommer Nanexa tillverka pr\u00f6vningsmaterial som kommer utv\u00e4rderas i en djurstudie i bolagets regi.<\/span><\/span><\/p>\n<p><span><span>Nanexa erh\u00e5ller en mindre betalning f\u00f6r det arbete som utf\u00f6rs. Djurstudien bekostas av biotechbolaget.<\/span><\/span><\/p>\n<p><span><span>F\u00f6retagets VD David Westberg kommenterar<\/span><\/span><\/p>\n<p><span><span>Det \u00e4r mycket gl\u00e4djande att utv\u00e4rderingen av PharmaShell\u00ae\u00a0gett bra resultat i den av biotechbolaget redan utf\u00f6rda utv\u00e4rderingen och att bolaget nu v\u00e4ljer att g\u00e5 vidare med en optimerad formulering i ytterligare en djurstudie. Jag ser detta som ett naturligt steg mot ett mer omfattande produktutvecklingsavtal och klinisk utv\u00e4rdering.<\/span><\/span><\/p>\n<p><span><span>F\u00f6r mer information kontakta:<br \/>\nDavid Westberg\u00a0&#8211;\u00a0VD, Nanexa AB (publ)Telefon: 0709 -42 83 03<br \/>\nE-post: david.westberg@nanexa.se www.nanexa.com<\/span><\/span><\/p>\n<p><span><span>Om Nanexa AB (publ)<\/span><\/span><\/p>\n<p><span><span>Nanexa AB \u00e4r ett nanoteknologiskt drug delivery-f\u00f6retag som fokuserar p\u00e5 utvecklingen av<\/span><\/span><\/p>\n<p><span><span>PharmaShell\u00ae\u00a0som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor<\/span><\/span><\/p>\n<p><span><span>potential inom ett flertal substanstyper och indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae<\/span><\/span><\/p>\n<p><span><span>utvecklar Nanexa egna projekt och har samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland<\/span><\/span><\/p>\n<p><span><span>AstraZeneca.<\/span><\/span><\/p>\n<p><span><strong><\/strong><\/span><\/p>\n<p><span><strong><\/strong><\/span><\/p>\n<div class=\"mfn-footer mfn-attachment\">\n<p><strong>Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a href=\"https:\/\/mb.cision.com\/Main\/12591\/3023673\/1185307.pdf\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Release<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>I slutet av 2018 tecknade\u00a0Nanexa ett &#34;Material Transfer Agreement&#34; med ett svensktbiotechbolag f\u00f6r utv\u00e4rdering av PharmaShell\u00ae\u00a0teknologin med deras specifika l\u00e4kemedelssubstans. Utv\u00e4rderingen har hittills gett bra resultat och bolaget har nu beslutat att ta projektet vidare med aktiviteter f\u00f6r att optimera formuleringen.<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\/\">L\u00e4s mer<\/a><\/p>\n","protected":false},"template":"","class_list":["post-3806","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa ut\u00f6kar samarbetet med svenskt biotechbolag - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa ut\u00f6kar samarbetet med svenskt biotechbolag - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"I slutet av 2018 tecknade\u00a0Nanexa ett &#034;Material Transfer Agreement&#034; med ett svensktbiotechbolag f\u00f6r utv\u00e4rdering av PharmaShell\u00ae\u00a0teknologin med deras specifika l\u00e4kemedelssubstans. Utv\u00e4rderingen har hittills gett bra resultat och bolaget har nu beslutat att ta projektet vidare med aktiviteter f\u00f6r att optimera formuleringen.L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\\\/\",\"name\":\"Nanexa ut\u00f6kar samarbetet med svenskt biotechbolag - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2020-01-30T12:07:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa ut\u00f6kar samarbetet med svenskt biotechbolag\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa ut\u00f6kar samarbetet med svenskt biotechbolag - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa ut\u00f6kar samarbetet med svenskt biotechbolag - Nanexa AB","og_description":"I slutet av 2018 tecknade\u00a0Nanexa ett &#34;Material Transfer Agreement&#34; med ett svensktbiotechbolag f\u00f6r utv\u00e4rdering av PharmaShell\u00ae\u00a0teknologin med deras specifika l\u00e4kemedelssubstans. Utv\u00e4rderingen har hittills gett bra resultat och bolaget har nu beslutat att ta projektet vidare med aktiviteter f\u00f6r att optimera formuleringen.L\u00e4s mer","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\/","name":"Nanexa ut\u00f6kar samarbetet med svenskt biotechbolag - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2020-01-30T12:07:14+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-utokar-samarbetet-med-svenskt-biotechbolag\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa ut\u00f6kar samarbetet med svenskt biotechbolag"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}